Investment
Features
FeesSafety
Academy
More
Pluang+

Compare JPMorgan Diversified Return International Eqty ETF (JPIN) vs Morgan Stanley (MS) Price & Performance

JPMorgan Diversified Return International Eqty ETFTrade
Morgan StanleyTrade

Price performance (Past 24H)

Key statistics

JPMorgan Diversified Return International Eqty ETF vs Morgan Stanley — how do they compare? JPMorgan Diversified Return International Eqty ETF trades at $73.09 (market cap $378.77M), while Morgan Stanley trades at $187.79 (market cap $294.39B). The key difference: Morgan Stanley is far larger — about 777.2× JPMorgan Diversified Return International Eqty ETF's market cap, and Morgan Stanley pays a 2.45% dividend while JPMorgan Diversified Return International Eqty ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Diversified Return International Eqty ETF for 120 Days and Morgan Stanley for 93 Days on average.

JPINMS
Market Cap
$378.77M$294.39B
Volume
13,8615,836,423
52-Week High
$77.80$228.42
52-Week Low
$64.96$151.86
Typical Hold Time
120 Days93 Days
Sector
—Financials
Enterprise Value
—$660.04B
Dividend Yield
—2.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

JPMorgan Diversified Return International Eqty ETF

JPIN, the JPMorgan Diversified Return International Equity ETF, trades at $72.94, down 0.42% on the day. Technical indicators are overwhelmingly bearish, with moving averages and oscillators signaling selling pressure, though RSI levels suggest potential oversold conditions. The ETF provides broad exposure to foreign large-cap value stocks, with a dividend scheduled for September 2026.

The outlook remains cautious due to weak technical momentum and lack of recent fundamental updates. Opportunities lie in international diversification and value exposure, but risks include global market volatility and ETF-specific underperformance. Investors should await fresh financial data for a clearer fundamental picture.

Morgan Stanley

Morgan Stanley (MS) trades at $189.71, down 0.66% with bearish technical signals despite strong fundamentals. The company has delivered three consecutive earnings beats with Q2 2026 EPS of $3.46 beating expectations by $0.57. Revenue growth accelerated to $66.0 billion in 2025 with net income margin expanding to 27.59%. Analyst consensus remains bullish with 55.77% buy ratings and a $229.25 price target representing 21% upside potential.

The investment case balances strong profitability and growth opportunities in wealth management and AI financing against concerning cash flow trends and technical weakness. While valuation appears reasonable at 15.14 P/E, investors face risks from volatile operating cash flows and rising debt levels. The stock offers attractive upside to analyst targets but requires monitoring of capital markets recovery timing.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

JPIN
100% Buy0% Sell
Avg holding period · 120 Days
MS
100% Buy0% Sell
Avg holding period · 93 Days

Top news

Latest headlines on both assets

About JPMorgan Diversified Return International Eqty ETF

The fund will invest at least 80% of its assets in securities included in the underlying index. The underlying index is comprised of equity securities across developed global markets (excluding North America) selected to represent a diversified set of factor characteristics.

Read more on JPIN →

About Morgan Stanley

Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.

Read more on MS →